Sage Therapeutics (SAGE) Q4 2024 earnings summary

Executive summary

• 2024 marked a pivotal year with the successful launch of ZURZUVAE for postpartum depression (PPD), treating over 6,600 women and surpassing expectations, driving commercial momentum into 2025.

• Strategic focus for 2025 includes expanding ZURZUVAE's reach, recalibrating R&D toward neuropsych and neurodevelopmental disorders, and maintaining financial discipline through pipeline prioritization and cost reduction.

• The board rejected Biogen's unsolicited acquisition proposal, initiating a strategic alternatives review to maximize shareholder value.

• Mission to pioneer brain health solutions and vision to lead in brain health innovation.

• Significant cost reductions in R&D and SG&A due to reorganization and pipeline prioritization, with further savings expected in 2025.

Financial highlights

• Collaboration revenue from ZURZUVAE sales reached $11.4M in Q4 2024 (up 4% sequentially) and $36.1M for the full year, representing 50% of Biogen's net revenues.

• Q4 2024 total revenue was $12.8M, down from $78.0M in Q4 2023; full year 2024 revenue was $41.2M, down from $86.5M in 2023.

• Net loss for Q4 2024 was $95.8M; full-year net loss was $400.7M, improved from $541.5M in 2023.

• R&D expenses for 2024 were $225.9M, down from $356.2M in 2023; SG&A expenses were $216.4M, down from $274.5M.

• Cash, cash equivalents, and marketable securities stood at $504M as of December 31, 2024, down from $753M at year-end 2023.

Outlook and guidance

• Existing cash and anticipated revenues (excluding potential milestones) are expected to fund operations through mid-2027.

• Operating expenses are projected to decrease substantially in 2025 due to pipeline prioritization and cost savings from the October 2024 reorganization.

• Increased investment in ZURZUVAE commercialization planned for 2025, with anticipated topline revenue growth and updates on SAGE-324 expected mid-2025.